Posted on 3/25/19
Cerveau Technologies Signs Research Agreement with Eisai
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in . . .
Posted on 3/22/19
Is Biogen a Bad-News Buy Now?
Wise drug developers say only fools rush in, but Biogen (NASDAQ:BIIB) couldn't help falling in love with early data for experimental Alzheimer's drug aducanumab about four . . .
Posted on 3/22/19
What's Next for Biogen After Its Alzheimer's Disease Drug Flop?
Another one bites the dust in the quest to develop an effective Alzheimer's disease treatment.Biogen (NASDAQ:BIIB) and its partner, Japanese drugmaker Eisai, announced that they would . . .
Posted on 3/22/19
HLTH and Boston Children's Hospital Partner to Launch Voice.HLTH Technology Showcase
HLTH, the largest and most important conference for health innovation, announced today a partnership with Boston Children's Hospital focused on voice technology in health.HLTH 2019 will . . .
Posted on 3/21/19
HLTH and Boston Children's Hospital Partner
HLTH, the largest and most important conference for health innovation, announced today a partnership with Boston Children's Hospital focused on voice technology in health.HLTH 2019 will . . .
Posted on 3/21/19
Tekla Healthcare Opportunities Fund Announces Renewal of Share Repurchase Program
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Opportunities Fund announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows . . .
Posted on 3/21/19
Ocular Therapeutix to Host 2019 Research & Development Day
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, . . .
Posted on 3/21/19
Sherlock Biosciences Launches With $35M Capital
Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced its launch and initial financing of $35 million.
Posted on 3/21/19
Buy Cigna At A Discount
SummaryCigna reported strong fourth quarter earnings that markets quickly ignored.Selling pressure pushed the stock lower after the Express Scripts deal.Stock trades at a discount to UnitedHealth . . .
Posted on 3/20/19
resTORbio Prices Public Offering of Common Stock
BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or . . .
Posted on 3/20/19
Alexion and Affibody Announce Partnership
BOSTON & SOLNA, Sweden--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently . . .
Posted on 3/20/19
Alexion and Zealand Pharma Announce Collaboration
BOSTON & COPENHAGEN, Denmark--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (NASDAQ:ZEAL) today announced a collaboration to discover and develop novel peptide therapies for complement-mediated . . .
Posted on 3/20/19
MilliporeSigma Opens First M Lab Collaboration Center in Europe
MilliporeSigma today officially opened its new M Lab Collaboration Center in Molsheim, France. The center is Millipore Sigma's first in Europe and ninth worldwide, providing biopharmaceutical . . .
Posted on 3/20/19
Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?
It doesn't look as if Bristol-Myers Squibb (NYSE:BMY) sought approval from its largest shareholders before offering Celgene (NASDAQ:CELG) a whopping $90 billion earlier this year.Starboard Value . . .
Posted on 3/20/19
PhysicianOne Urgent Care and Wellforce Announce Partnership
PhysicianOne Urgent Care and Wellforce today announced a partnership to provide coordinated urgent care to patients at PhysicianOne Urgent Care's four locations across Greater Boston. PhysicianOne . . .
Posted on 3/19/19
New Study: Reusable Bronchoscopes Cost More Than Sterile Single-use Bronchoscopes
Study urges hospitals to consider obtaining sterile single-use bronchoscopes for routine procedures to improve hospital economy and patient safety. Bronchoscopes – one of the most commonly . . .
Posted on 3/19/19
Here's Why Karyopharm Therapeutics Climbed Today
What happenedShares of Karyopharm Therapeutics (NASDAQ:KPTI), a clinical-stage biopharmaceutical business, rose 12.7% on Monday after investors had a chance to digest the company's latest investor presentation. . . .
Posted on 3/18/19
resTORbio Proposes Public Offering of Common Stock
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent . . .
Posted on 3/18/19
Thermo Fisher Scientific to Invest $150 Million to Expand Pharma Services Capabilities
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it is investing $150 million in its Pharma Services business to . . .
Posted on 3/18/19
Myomo Announces New Sales and Service Agreement for Italy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, . . .
Posted on 3/18/19
Imara Closes a $63M Series B Cross-Over Financing
Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, today announced the closing of an oversubscribed $63 million
Posted on 3/18/19
Karuna Raises $68M Series B Financing
Karuna Therapeutics, Inc., focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders including psychosis in schizophrenia
Posted on 3/18/19
For Bristol-Myers Squibb's Sake, Celgene Merger Should Be Voted Down
SummaryCelgene has been struggling in its oncology segment.23% of assets are in goodwill, with the risk of a writedown.Starboard Value is calling shenanigans and could sue . . .
Posted on 3/18/19
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Bristol-Myers Squibb (NYSE:BMY) shocked everybody when it announced its $74 billion acquisition of Celgene (NASDAQ:CELG) earlier this year. Not everyone was happy, with the merger drawing . . .
Posted on 3/14/19
PharmMD Changes Company Name to AdhereHealth
Reflects vision of better health through medication adherence by resolving social determinants through disruptive technologies, engagement services and home-delivered pharmacy PharmMD™, a leading healthcare technology company . . .

